1. Membrane Transporter/Ion Channel MAPK/ERK Pathway Stem Cell/Wnt NF-κB Apoptosis
  2. Sodium Channel MEK ERK NF-κB Apoptosis
  3. Lidocaine hydrochloride

Lidocaine hydrochloride  (Synonyms: Lignocaine hydrochloride)

Cat. No.: HY-B0185A Purity: 99.96%
COA Handling Instructions

Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative and a agent to treat ventricular arrhythmia and an effective tumor-inhibitor.

For research use only. We do not sell to patients.

Lidocaine hydrochloride Chemical Structure

Lidocaine hydrochloride Chemical Structure

CAS No. : 73-78-9

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
USD 61 In-stock
Solution
10 mM * 1 mL in DMSO USD 61 In-stock
Solid
500 mg USD 55 In-stock
5 g USD 66 In-stock
10 g USD 106 In-stock
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 12 publication(s) in Google Scholar

Other Forms of Lidocaine hydrochloride:

Top Publications Citing Use of Products

    Lidocaine hydrochloride purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2017 Nov 2;14(1):211.  [Abstract]

    Immunoblot results demonstrate that Lidocaine inhibits Morphine-induced upregulation of phosphorylation of p38 MAPK, but not the p38 total protein.

    View All MEK Isoform Specific Products:

    View All ERK Isoform Specific Products:

    View All NF-κB Isoform Specific Products:

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative and a agent to treat ventricular arrhythmia and an effective tumor-inhibitor[2].

    IC50 & Target[1,2]

    MEK

     

    ERK

     

    NF-κB

     

    In Vitro

    Lidocaine hydrochloride (Lignocaine hydrochloride) (10 nM; 48 hours) decreases significantly cell proliferation[2].
    Lidocaine hydrochloride (1-10 nM; 24-72 hours) inhibits cell viability and achieves the most suppressing effects at the concentration of 10 nM and treatment time 48 hours[2].
    Lidocaine hydrochloride (10 nM; 48 hours) increases significantly the apoptotic cell rate[2].
    Lidocaine hydrochloride (10 nM; 48 hours) down-regulates Cyclin D1 and up-regulates p21 expression significantly[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Proliferation Assay[2]

    Cell Line: The human gastric cancer cell line MKN45
    Concentration: 10 nM
    Incubation Time: 48 hours
    Result: Decreased significantly cell proliferation.

    Cell Viability Assay[2]

    Cell Line: The human gastric cancer cell line MKN45
    Concentration: 1, 5 and 10 nM
    Incubation Time: 24, 48, 72 hours
    Result: Inhibited MKN45 cell viability.

    Apoptosis Analysis[2]

    Cell Line: The human gastric cancer cell line MKN45
    Concentration: 10 nM
    Incubation Time: 48 hours
    Result: Increased significantly the apoptotic cell rate.

    Western Blot Analysis[2]

    Cell Line: The human gastric cancer cell line MKN45
    Concentration: 10 nM
    Incubation Time: 48 hours
    Result: Down-regulated Cyclin D1 and up-regulated p21 expression significantly.
    In Vivo

    Lidocaine hydrochloride (Lignocaine hydrochloride) causes completely reversible tail nerve block in rats. Mechanical nociception block produced by lidocaine has slower onset and faster recovery compared with thermal nociception block[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    Molecular Weight

    270.80

    Formula

    C14H23ClN2O

    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(NC1=C(C)C=CC=C1C)CN(CC)CC.[H]Cl

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage

    4°C, sealed storage, away from moisture and light

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

    Solvent & Solubility
    In Vitro: 

    H2O : ≥ 100 mg/mL (369.28 mM)

    DMSO : ≥ 100 mg/mL (369.28 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.6928 mL 18.4638 mL 36.9276 mL
    5 mM 0.7386 mL 3.6928 mL 7.3855 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (9.23 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (9.23 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 120 mg/mL (443.13 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Purity & Documentation

    Purity: 99.96%

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 3.6928 mL 18.4638 mL 36.9276 mL 92.3191 mL
    5 mM 0.7386 mL 3.6928 mL 7.3855 mL 18.4638 mL
    10 mM 0.3693 mL 1.8464 mL 3.6928 mL 9.2319 mL
    15 mM 0.2462 mL 1.2309 mL 2.4618 mL 6.1546 mL
    20 mM 0.1846 mL 0.9232 mL 1.8464 mL 4.6160 mL
    25 mM 0.1477 mL 0.7386 mL 1.4771 mL 3.6928 mL
    30 mM 0.1231 mL 0.6155 mL 1.2309 mL 3.0773 mL
    40 mM 0.0923 mL 0.4616 mL 0.9232 mL 2.3080 mL
    50 mM 0.0739 mL 0.3693 mL 0.7386 mL 1.8464 mL
    60 mM 0.0615 mL 0.3077 mL 0.6155 mL 1.5387 mL
    80 mM 0.0462 mL 0.2308 mL 0.4616 mL 1.1540 mL
    100 mM 0.0369 mL 0.1846 mL 0.3693 mL 0.9232 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email Address *

    Phone Number *

     

    Organization Name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Lidocaine hydrochloride
    Cat. No.:
    HY-B0185A
    Quantity:
    MCE Japan Authorized Agent: